RESULTS from the 21-year
Betaferon Long-term Follow-up
Study have shown that patients
with multiple sclerosis treated
earlier with Betaferon 250 ug
(interferon beta-1b) had a 46.8%
risk reduction in the rate of death
at the long-term follow-up, compared
with patients receiving placebo for
up to the first five years of treatment.The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 08 May 12 To see the full story, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 08 May 12
MEDADVISOR pharmacies have recorded over 80,000 flu vaccinations via PlusOne so far this year, which when combined with available data from the Pharmacy Guild highlights a near doubling of vaccinations delivered in pharmacy in Apr and May this year.
AUSTRALIAN-LISTED cannabidiol (CBD) cosmetics and BioPharma group MGC Pharmaceuticals has announced via the ASX that its MGC Derma CBD based cosmetics collection will be sold on the ground floor of the Beyond Beauty Department within Knightsbridge (pictured) as well as through E-Commerce stores at luxury retailer Harvey Nichols, commencing from 29 Jun 2018.